A Phase I Single Dose Study of SA-237 in Healthy Volunteers
Latest Information Update: 20 May 2020
At a glance
- Drugs Satralizumab (Primary) ; Satralizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 01 May 2020 Results of populaion PK model-predicted exposure of satralizumab doses from two phase 2 clinical studies: SAkuraStar, SAkuraSky and a phase 1 satralizumab trial were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 01 May 2020 Results assessing pharmacological characteristics (pharmacokinetics and pharmacodynamics) from two clinical studies (SAkuraSky and SAkuraStar; n=104 NMOSD patients), Japanese healthy volunteers (n=72) and in rheumatoid arthritis (JapicCTI121786; n=33) patients were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 11 Sep 2016 New trial record